<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04966273</url>
  </required_header>
  <id_info>
    <org_study_id>20-EU-01</org_study_id>
    <nct_id>NCT04966273</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Effectiveness of the Biosensors Microcatheter in Coronary Chronic Total Occlusions (CTO) - BIOMICS</brief_title>
  <acronym>BIOMICS</acronym>
  <official_title>A Prospective, Multi-Center, Non-randomized, Single Arm, Open Label, Study to Evaluate the Safety and Effectiveness of the Biosensors Microcatheter in Coronary Chronic Total Occlusions (CTO) - BIOMICS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biosensors Europe SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biosensors Europe SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Biosensors, the Sponsor would like to determine if the Biosensors Microcatheter is safe and&#xD;
      effective in treating patients with CTO by assessing a composite of in-hospital cardiac death&#xD;
      or myocardial infarction and device success (defined as successfully facilitate placement of&#xD;
      a guidewire beyond the occluded coronary segment), respectively.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, multi-center, open-label single-arm trial designed to enroll 100 patients&#xD;
      undergoing attempted CTO-PCI at up to 10 centers in the United Kingdom and N. Ireland. For&#xD;
      assessment of efficacy, the ability of the BM to successfully facilitate placement of a&#xD;
      guidewire beyond the occluded coronary segment will be assessed. Patients will be followed up&#xD;
      until hospital discharge or 7 days post index procedure, whichever comes first. For the&#xD;
      assessment of safety, the incidence of in-hospital cardiac death or myocardial infarction&#xD;
      will be assessed at hospital discharge or 7 days post index procedure, whichever comes first.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: Percentage of patients with device success</measure>
    <time_frame>Follow-up only up to hospital discharge or 7 days maximum post procedure, whichever comes first.</time_frame>
    <description>Device success defined as successful placement of a guidewire in the vessel across the occluded coronary segment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Percentage of patients with composite of in-hospital cardiac death or myocardial infarction.</measure>
    <time_frame>Follow-up only up to hospital discharge or 7 days maximum post procedure, whichever comes first.</time_frame>
    <description>Composite of in-hospital cardiac death or myocardial infarction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with technical success</measure>
    <time_frame>Follow-up only up to hospital discharge or 7 days maximum post procedure, whichever comes first.</time_frame>
    <description>Technical success is defined as achievement of TIMI grade 2 antegrade flow with less than 50% residual stenosis of the target CTO lesion at procedure end</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with procedural success</measure>
    <time_frame>Follow-up only up to hospital discharge or 7 days maximum post procedure, whichever comes first.</time_frame>
    <description>Procedural success defined as technical success plus the absence of in-hospital MACE (death, myocardial infarction or clinically-driven target vessel revascularization (cd TVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with crossing success</measure>
    <time_frame>Follow-up only up to hospital discharge or 7 days maximum post procedure, whichever comes first.</time_frame>
    <description>Crossing success defined as the BM crossing the lesion</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of patients with device-related perforation</measure>
    <time_frame>Follow-up only up to hospital discharge or 7 days maximum post procedure, whichever comes first.</time_frame>
    <description>Device-related perforation at the site of target coronary lesion and/or its proximal reference segment including donor artery or collateral</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of patients with device failure</measure>
    <time_frame>Follow-up only up to hospital discharge or 7 days maximum post procedure, whichever comes first.</time_frame>
    <description>Device failure is defined as:&#xD;
any evidence of fracture of any part of the microcatheter,&#xD;
evidence of wire puncture of any part of the device&#xD;
and/or evidence of a fragment being retained in the body of the patient after a procedure.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <arm_group>
    <arm_group_label>Biosensors Microcatheter (BM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use of Biosensors Microcatheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Microcatheter</intervention_name>
    <description>Only to be used if Biosensor Microcatheter does not perform accordingly</description>
    <arm_group_label>Biosensors Microcatheter (BM)</arm_group_label>
    <other_name>Standard hospital Microcatheter</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult aged &gt; 18 years&#xD;
&#xD;
          2. Patient understands and has signed the consent form.&#xD;
&#xD;
          3. Patient has an angiographically documented chronic total occlusion (i.e. estimated to&#xD;
             be &gt;3 months duration) showing distal TIMI 0 flow. Occlusion with absence of antegrade&#xD;
             flow through the lesion and with a presumed or documented duration of 3 months.&#xD;
&#xD;
          4. Suitable candidate for non-emergent PCI&#xD;
&#xD;
          5. Left ventricle ejection fraction &gt; 25%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient unable to give informed consent.&#xD;
&#xD;
          2. Current participation in another study with any investigational drug or device.&#xD;
&#xD;
          3. Known or suspected contrast allergy.&#xD;
&#xD;
          4. in-stent CTO.&#xD;
&#xD;
          5. Planned treatment of a second CTO during the index procedure&#xD;
&#xD;
          6. Intolerance to Aspirin and/or inability to tolerate a second antiplatelet agent&#xD;
             (Clopidogrel or Prasugrel or Ticagrelor).&#xD;
&#xD;
          7. Recent major cerebrovascular event (history of stroke or TIA within 1 month)&#xD;
&#xD;
          8. Renal insufficiency (serum creatinine of &gt; 200Î¼mol/L)&#xD;
&#xD;
          9. Active gastrointestinal bleeding&#xD;
&#xD;
         10. Active infection or fever that may be due to infection&#xD;
&#xD;
         11. Life expectancy &lt; 2 years due to other illnesses&#xD;
&#xD;
         12. Significant anaemia (haemoglobin &lt; 10.0g/L)&#xD;
&#xD;
         13. Severe uncontrolled systemic hypertension (&gt; 240 mmHg within 1 month of procedure)&#xD;
&#xD;
         14. Severe electrolyte imbalance&#xD;
&#xD;
         15. Congestive heart failure [New York Heart Association (NYHA) Class III\IV] CSA Class&#xD;
             IV.&#xD;
&#xD;
         16. Unstable angina requiring emergent PCI or coronary artery bypass graft (CABG)&#xD;
&#xD;
         17. Recent myocardial infarction (MI) (within the past one week)&#xD;
&#xD;
         18. Unwillingness or inability to comply with any protocol requirements&#xD;
&#xD;
         19. Subject is pregnant or nursing. Female subjects of child-bearing potential must have a&#xD;
             negative pregnancy test done within 7 days prior to the index procedure per site&#xD;
             standard test.&#xD;
&#xD;
         20. Extensive prior dissection from a coronary guidewire use&#xD;
&#xD;
         21. Drug abuse or alcoholism.&#xD;
&#xD;
         22. Patients under custodial care.&#xD;
&#xD;
         23. Bleeding diathesis or coagulation disorder&#xD;
&#xD;
         24. Kawasaki's disease or other vasculitis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simon Walsh, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Belfast HSC Trust, Royal Victoria Hospital, Belfast, BT12 6BA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Margaret MCENTEGART, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Golden Jubilee National Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Keith Oldroyd, Prof.</last_name>
    <phone>+41 21 804 8000</phone>
    <email>k.oldroyd@biosensors.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Diana Schuette, Dr.</last_name>
    <phone>+41 21 804 8000</phone>
    <email>d.schuette@biosensors.com</email>
  </overall_contact_backup>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 30, 2021</study_first_submitted>
  <study_first_submitted_qc>July 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2021</study_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Total Occlusion (CTO)</keyword>
  <keyword>Microcatheter</keyword>
  <keyword>CTO-PCI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The emphasis in all scientific publications and presentations will be placed on the endpoint at discharge.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

